公司資料
PAVmed 股價、新聞與催化劑
- 股票代碼:
- PAVM
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
5.33 USD (+2.40%)
收盤價
最後更新: 2026年8月17日
43M USD
市值
股價為何變動
Following the latest company update, “PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results”, PAVM closed up 9.70% at $5.20 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
公司概覽
Diversified Medical Technology Portfolio
PAVmed is a diversified commercial-stage medical technology company with businesses spanning diagnostic testing, digital health, and implantable medical devices. It develops products through both majority-owned subsidiaries and internally managed device programs.
Lucid Esophageal Diagnostics
Lucid Diagnostics commercializes the EsoGuard DNA test and EsoCheck cell-collection device for detecting esophageal precancer associated with gastroesophageal reflux disease. The platform is designed to identify at-risk patients before progression to esophageal adenocarcinoma.
Veris Cancer Monitoring
Veris Health is developing a digital oncology platform for remote monitoring of patients receiving cancer treatment. Its implantable physiologic monitor is intended to be placed during chemotherapy-port implantation and provide continuous data that may support earlier detection of treatment complications.
PortIO
PortIO is an implantable intraosseous vascular-access device intended to provide long-term access through bone rather than conventional veins. Early clinical work has evaluated device patency and usability as PAVmed prepares for further regulatory interaction.
Octeris
Octeris is a multimodal endoscopic imaging probe designed to provide real-time tissue characterization during endoscopic procedures. PAVmed is preparing a clinical validation study with the University of North Carolina to assess the technology in a clinical setting.
未來催化劑
- Submission of an FDA pre-submission meeting request for PortIO in Q4 2026.
- FDA 510(k) submission for the Veris implantable physiologic monitor in early 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。